A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

NCT06756321 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/refractory Lymphoma
Relapsed/Refractory Leukemia

Interventions

BIOLOGICAL: anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Affiliated Hospital of Nantong University

Collaborators

[object Object]